Serum interleukin-6 in seropositive rheumatoid arthritis and response to tocilizumab: An observational study.

Eur J Rheumatol · 2022 · PMC10089141 · PMID 35110134

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Main Points More RA patients with relatively lower baseline serum IL-6 attained DAS28 remission following tocilizumab treatment as compared to those with higher baseline serum IL-6, although it did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.